NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
May 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
NUBAIN (nalbuphine hydrochloride) by Pfizer is clinical pharmacology mechanism of action nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. First approved in 1979.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUBAIN (nalbuphine hydrochloride) is a mixed opioid agonist-antagonist analgesic approved in 1979 for moderate to severe pain management and respiratory insufficiency. It works by acting as an agonist at kappa opioid receptors while antagonizing mu opioid receptors, providing analgesic potency equivalent to morphine up to 30 mg with a built-in ceiling effect on respiratory depression.
LOE Approaching
As LOE approaches, brand team focus shifts from growth to market defense and specialty channel maintenance; expect consolidated team structure with emphasis on retention and cost management.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. Pharmacodynamics Nalbuphine hydrochloride injection is a potent analgesic. Its analgesic potency is essentially equivalent to that of morphine on a milligram basis…
Worked on NUBAIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.